Evidence map›Paper›PMID 35286523›Full record

ArticleBreast cancer research and treatment2022

Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study.

Oliver William Scott, Sandar Tin Tin, J Mark Elwood, Alana Cavadino, Laurel A Habel, Marion Kuper-Hommel, Ian Campbell, Ross Lawrenson

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Beta-blocker use and breast cancer outcomes: a meta-analysis.Breast cancer research and treatment · 2024
    Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Oliver William ScottDepartment of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Building 507, 85 Park Road, Grafton, Auckland, 1023, New Zealand. o.scott@auckland.ac.nz.ORCID http://orcid.org/0000-0002-8994-2760
Sandar Tin TinDepartment of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Building 507, 85 Park Road, Grafton, Auckland, 1023, New Zealand.
J Mark ElwoodDepartment of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Building 507, 85 Park Road, Grafton, Auckland, 1023, New Zealand.
Alana CavadinoDepartment of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Building 507, 85 Park Road, Grafton, Auckland, 1023, New Zealand.
Laurel A HabelDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Marion Kuper-HommelDepartment of Oncology, Waikato District Health Board, Hamilton, New Zealand.
Ian CampbellDepartment of Strategy, Investment and Transformation, Waikato District Health Board, Hamilton, New Zealand.
Ross LawrensonDepartment of NIDEA (National Institute of Demographic and Economic Analysis), Waikato Medical Research Centre, University of Waikato, Hamilton, New Zealand.
University of Auckland · NZKaiser Permanente · USUniversity of Waikato · NZWaikato District Health Board · NZWaikato Hospital · NZ

Funding

Auckland Medical Research Foundation 1118017Auckland Medical Research Foundation 1217004
6 · The paper itself

Abstract

purposeBeta blockers (BB) have been associated with improved, worsened, or unchanged breast cancer outcomes in previous studies. This study examines the association between the post-diagnostic use of BBs and death from breast cancer in a large, representative sample of New Zealand (NZ) women with breast cancer.

methodsWomen diagnosed with a first primary breast cancer between 2007 and 2016 were identified from four population-based regional NZ breast cancer registries and linked to national pharmaceutical data, hospital discharges, and death records. The median follow-up time was 4.51 years. Cox proportional hazard models were used to estimate the hazard of breast cancer-specific death (BCD) associated with any post-diagnostic BB use.

resultsOf the 14,976 women included in analyses, 21% used a BB after diagnosis. BB use (vs non-use) was associated with a small and nonstatistically significant increased risk of BCD (adjusted hazard ratio: 1.11; 95% CI 0.95-1.29). A statistically significant increased risk confined to short-term use (0-3 months) was seen (HR = 1.40; 1.14-1.73), and this risk steadily decreased with increasing duration of use and became a statistically significant protective effect at 3 + years of use (HR = 0.55; 0.34-0.88).

conclusionOur findings suggest that any increased risk associated with BB use may be driven by risk in the initial few months of use. Long-term BB use may be associated with a reduction in BCD.

Indexed as

Breast NeoplasmsNeoplasms, Second PrimaryAdrenergic beta-AntagonistsCohort StudiesFemaleHumansProportional Hazards ModelsAdrenergic beta-AntagonistsBeta blockersBreast cancerCohort studyMortalityPharmacoepidemiology

Identifiers

PMID35286523
PMCPMC8993732
OpenAlexW4220779215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.